Trade Framework for Funding Research and Development
117th WHO Executive Board Resolution on a Global Framework for
Essential Health Research and Development
- May, 2006. James Love. Bulletin of the World Health Organization. 84 (5).
Drug development incentives to improve
access to essential medicines.
- February 24, 2005.
Sign on letter to the World Health Organizations's Commission on Intellectual
Property, Innovation and Health The letter asks the Commission to
evaluate a new treaty framework for medical R&D.
- February 7, 2005.
Draft Version 4 of the proposed Medical Research and Development Treaty.
- July 22, 2004. Consumer Project on Technology, Consumers Union, Consumer Federation
of America, Health Action International, Essential Action, and Consumer Action.
Joint letter to US Trade Representative Robert Zoellick.
- July 1, 2004
CPTech comments on US Department of Commerce, DHHS and USTR Study
of International Drug Pricing, proposing R&D+ as alternative
- June, 2004. James Love and Tim Hubbard in Bridges.
Make Drugs Affordable: Replace TRIPs-plus by R&D-plus.
- March 4, 2004. Op-ed by James Love and Tim Hubbard published in the Guardian.
We're Patently Going Mad: Lifesaving drugs must be developed differently -
for all our sakes.
Here is James V. Delong's rather
rambling attack on the Guardian article,
which links quite a few different issues, proposals and movements
- February 2, 2004. Essay by James Love and Tim Hubbard published in the PLoS Biology.
A New Trade Framework for Global Healthcare R&D.
- December 4, 2003. Paper presentend by James Love at Columbia University's
Workshop on Access to Medicines and the Financing of Innovations in Heath Care.
A New Trade Framework for Global Healthcare R&D. Also, see the
Conference Home Page.
- July 7, 2003. Letter from 63 experts and stakeholdedras to
Kamil Idris, Director-General of WIPO,
requesting that WIPO host a meeting on open collaborative development
models. Available in
and plain text.
- June 24, 2003. Tim Hubbard and James Love. Paper presented at the
Meeting on The Role of Generics and Local Industry in Attaining the Millennium
Development Goals (MDGs) in Pharmaceuticals and Vaccines held at the World Bank.
An Agenda for Research and Development.
- June 14, 2003. Tim Hubbard and James Love in the New Scientist.
Medicines without barriers.
- May 27, 2003 James Love.
From TRIPS to RIPS: A better Trade Framework to support Innovation in
Medical Technologies. (MS Word format) Presented at the Workshop on
Economic issues related to access to HIV/AIDS care in developing countries,
Agence nationale de recherches sur le sida, Marsielle, France.
- April 29, 2003. James Love. Presentation at the Meeting on global
framework for supporting health research and development (R&D) in areas of
market and public policy failure, Geneva, Switzerland.
Basis for a treaty on R&D.
- December 3, 2002. James Love. PPT presentation given at
The Drugs for Neglected Diseases (DND) Working Group, in Rio de
The Benifits of a Treaty on R&D.
CPTech Page on Request for WIPO Meeting on Collaborative Development Models
Open Develpment Models for Medical and Scientific Research.
- WTO Documents
- WHO Documents
- July 26, 2005. Professor Luigi Ortenigo of Brescia University.
Comments on the Proposed Medical R&D Treaty.
- February 22, 2005. Nicoletta Dentico and Nathan Ford, from the MSF
Neglected Disease Group. Article published in PLoS Medicine.
The Courage to Change the Rules: A Proposal for an Essential Health R&D Treaty.
- September 22, 2004. Dean Baker, Center for Economic and Policy Research.
Financing Drug Research: What Are the Issues?"
- June 25, 2004. Joseph A. DiMasi and Henry G. Grabowski.
Patents and R&D Incentives: Comments on the Hubbard and Love Trade
Framework for Financing Pharmaceutical R&D.
- November 12, 2003. John Barton.
Preserving the Global Scientific and Technological Commons.
- September 25, 2003. Mark B McClellan, Commissioner of the US Food and Drug Administration.
Speech before the First International Colloquium on Generic Medicine.
- September 19, 2003. David Dickson for the Science and Development Network.
Cancún's failure raises need for collaborative science.
- July 10, 2003. Declan Butler for Nature, vol 424.
Drive for patent-free innovation gathers pace.
Text of story on www.nature.com (password required), or click
here for the version on the ip-health archives.
October 30, 2003. William Steiger, US Department of Health and Human Services,
letter to the World Health Organziation
bit mapped image of letter
ocr image of letter)
setting out US government views on the terms of reference and membership of
the proposed commission on innovation, Intellectual Property Rights
and public health. (CIPIH)
This document provided an aggressive defensive of the strong IPR model
for financing innovative, rejecting suggestions for more focus on open medicine
models, open journals, R&D treaties or other non-proprietary models.
Some quotes from the memo follow:
"The body should not be engaged in considering amendment to existing
international legal or trade instruements or new instruments such as an
international research and development (R&D) treaty.
"In contrast, the current thinking of many non-government organizations (NGOs)
is that there neeeds to be an expansion of "open source" research.
Non-proprietary research, however, generally does not stimulate the
intensive investment necessary to transform basic technologies into
innovative products because there is no prospect of exclusivity to reward
the risk of devoting scare capital to product development. . .
"In particularly,the group should consider new incentives that stimulate
research for priority diseases of developing countries to broaden the
beneficiaries of biomedical innovation, including models such as
transferable rights of market exclusivity. . .
"Much recent discussion has been generated on the need to provide free
access to medical jouranls to research communities in developing countries
as a way of bridging the health information gap. Much of this information
is already available--for developed and developing countries alike--in no-cost
(free) databases, including patent databases easily accessible on the Internet.
. . . An anti-patent policy ensures that valuable research and technology
know-how is not patented, and is therefore not disclosed to the public.
Op-Ed Columns on Trade and Research
Neglected Diseases - Diseases for which there is Little or No Research